US Privacy Statement
US Privacy Statement
Search
FDA Approves sNDA for BI’s Stiolto® Respimat® | BI US
FDA approves an sNDA for STIOLTO® RESPIMAT® (tiotropium bromide & olodaterol) showing improvement in quality of life in COPD patients. View ISI, PI & Med Guide.
New effort to help improve C-R-M health outcomes
Boehringer Ingelheim sponsors American Heart Association's Cardiovascular Kidney Metabolic Health Intiative (CKMH)
Boehringer Ingelheim Grass Roots Innovation: Supporting life-science innovators
Boehringer Ingelheim Grass Roots Innovation program supports life-science innovators with mentoring, networking and education activities to help them advance their science
A Brave New World: Digital Health Redo | Boehringer Ingelheim US
Find out more on how digital innovation in Boehringer Ingelheim is transforming the world of animal health, including disease prevention and vaccination.
Hurricane help: Our unwavering support of storm victims
Ensuring access to healthcare, meals, and medication for people and animals across the southeast.
Open Innovation at Boehringer Ingelheim
Open Innovation at Boehringer Ingelheim
Patients with a rare and aggressive form of liposarcoma need treatment advances
Patients with a rare and aggressive form of liposarcoma need treatment advances
Collaboration with Mary Tyler Moore Vision Initiative
Boehringer Ingelheim joins forces with Mary Tyler Moore Vision Initiative to combat vision loss from diabetes
BI Beyond Borders: Science, Collaboration, Geography | BI US
Read more on how the Company’s ‘radar’ for the next big wave of innovation, the RBB team, is tasked with exploring emerging science and technologies.
Results from Phase II MASH trial announced at EASL 2024
Boehringer Ingelheim announced results from Phase II trial in metabolic dysfunction-associated steatohepatitis (MASH) at EASL 2024
Ingelheim
The company headquarters of Boehringer Ingelheim are located in Ingelheim, Germany.
Internal application
Internal applications | FAQ
Once-Daily Dosing for Most Diabetic Dogs | Boehringer Ingelheim US
Find out more on the BI PROZINC® (protamine zinc recombinant human insulin) for most canine diabetics, a breakthrough for pet owners with diabetic dogs.
Building lasting partnerships for a better future
Working with the University of Georgia, we’ve co-created a sustainability training initiative that benefits people, animals and the planet.
Fighting Rabies from the Air | Boehringer Ingelheim US
Click here to read more on how Boehringer Ingelheim is fighting diseases from the air, preventing the spread of the disease with our vaccine.
Matthias Muenks
Matthias Muenks, Global Engineering Process and Data Manager at Boehringer Ingelheim, speaks about the pharmaceutical company’s innovation and culture.
Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018
Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018
FDA Grants BTD for Investigational Treatment of CIAS | BI US
Learn about the breakthrough therapy designation grant for BI's latest investigational treatment of cognitive impairment associated with schizophrenia.
Online application
Online application | FAQ
Fighting Non-Communicable Diseases | Boehringer Ingelheim US
Read more on Boehringer Ingelheim's new NCD initiative, aiming to reduce NCD prevalence and capture the impact of our product portfolio for our patients.
Corporate Compliance Program
Our E&C Program conforms with the principles and recommendations published in guides from various Federal agencies and industry related organizations
FDA Reaffirms Safety of Pradaxa® (dabigatran etexilate) | Boehringer Ingelheim US
An FDA study found that PRADAXA was associated with reduced risks of ischemic stroke, intracranial hemorrhage & death. View ISI, PI & Med Guide.
Patient Assistance Program
Patient Assistance Program
Update on sNDA for fibrosing ILD in children and adolescents
Press release providing an update on FDA review of sNDA in children and adolescents with fibrosing interstitial lung disease (ILD)